Abstract: The invention provides, inter alia, conjugates of a hydratable polymer (such as PEG, polyethylene glycol) and a lectin (such as wheat germ agglutinin, WGA), compositions comprising these conjugates, as well as methods and targeted uses of these conjugates and compositions for, e.g., lubricating, maintaining hydration of, rehydrating, and/or inhibiting microorganism colonization of a biological surface in need thereof.

Abstract: The present invention provides a hemostatic porous composite sponge comprising i) a matrix of a biomaterial and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that said polymeric component is coated onto a surface of said matrix of a biomaterial, or said matrix is impregnated with said polymeric material, or both.

Abstract: Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. These heating units can be actuated by electrical resistance, by optical ignition or by percussion. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.

Abstract: A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.

Abstract: The present invention describes methods and tools for preparing a population of monodisperse polymer microparticles, which are of particular interest in the field of drug delivery.

Abstract: Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity are also provided as are uses of the inventive compositions.

Abstract: Provided is a method of obtaining biologically active recombinant human G-CSF from inclusion bodies, wherein the solubilization and refolding process can be performed at ambient temperature and the purification step comprises reversed phase chromatography (RP), in particular RP-HPLC. The G-CSF preparation so obtained is characterized by high purity and homogeneity.

Abstract: Helicobacter pylori is closely associated with chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma. Helicobacter pylori neutrophil-activating protein (HP-NAP), a virulence factor of Helicobacter pylori, plays an important role in pathogenesis of Helicobacter pylori infection. Since HP-NAP has been proposed as a candidate vaccine against Helicobacter pylori infection, an efficient way to obtain pure HP-NAP needs to be developed. In the present invention, recombinant HP-NAP expressed in Bacillus subtilis and Escherichia coli was purified through a single step of DEAE SEPHADEX ion-exchange chromatography with high purity. Also, purified recombinant HP-NAP was able to stimulate neutrophils to produce reactive oxygen species. Thus, recombinant HP-NAP obtained from our Bacillus subtilis expression system and Escherichia coli expression system is functionally active.

Abstract: This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not. The conjugate is then desorbed from the membrane, yielding a solution that is substantially reduced in free carbohydrate.

Abstract: Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. These heating units can be actuated by electrical resistance, by optical ignition or by percussion. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.

Abstract: The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.

Abstract: The invention concerns wheat germ ferment, its biologically active fractions, the process for their production, the pharmaceutical preparations containing them and their uses.

Abstract: The invention claims a process for making an insulin-oligomer conjugate IN-105. IN-105 precursor having formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain] is cloned and expressed in Pichia. The biosynthetic precursor is then conjugated with an activated oligomer. The IN-105 precursor-oligomer conjugate is then treated with protease and purified to afford active insulin-oligomer conjugate of formula insulin-OC—CH2—CH2—(OCH2CH2)3—OCH3.

Abstract: The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.

Abstract: The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.

Abstract: Described is a method for the preparation of a mixture of peptides, having an arginine and lysine content of at least 20 w/w %, based on the protein content, from at least one protein source, to a preparation comprising a mixture of arginine- and lysine-rich peptides, comprising at least 20 w/w % arginine and lysine, and to the use of the said preparation as active compound in a medicament, supplement, beverage or food product.

Abstract: Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity are also provided as are uses of the inventive compositions.

Abstract: Black currant anthocyanin-containing compositions for foods comprising 1 to 25% by weight of black currant anthocyanin on the basis of solid matters; a process for producing a black currant anthocyanin-containing composition for foods characterized by purifying and concentrating black currant juice employed as a starting material by using a charged reverse osmosis membrane; functional foods and drinks characterized by containing the above compositions for foods; and the above-described compositions for foods and the above-described functional foods and drinks having an effect of improving visual function, a function of improving blood fluidity, and/or a function of lowering blood pressure. The conventional black currant anthocyanin compositions have a low black currant anthocyanin content, strong acidity and poor stability, which makes them unsuitable as additives for foods and drinks.

Abstract: Provided is a method of purifying a vancomycin from a fermentation broth of a microorganism containing vancomycin, including passing the fermentation broth of a microorganism containing vancomycin through a strong acid cation exchange resin, a weak base anion exchange resin, alumina and a hydrophobic absorbent resin sequentially.

Abstract: A biocompatible fluid adhesive protein foam, which is bioresorbable and nontoxic, for surgical and/or therapeutic use, in particular for protecting/cicatrizing tissue wounds and for attaching biological tissues to each other or to an implanted biomaterial. The biocompatible fluid adhesive protein foam includes a biocompatible fluid adhesive protein matrix, which is bioresorbable and nontoxic, containing a biocompatible and nontoxic gas or mixture of gases. Further, a process and a kit for preparing such a foam are provided.

Abstract: A scalable method for the production of highly purified plasmid DNA in Escherichia coli is described, which method includes growing plasmid-containing cells to a high biomass in exponential growth and lysing the cells by raising the pH of the culture to a carefully controlled pH value in which chromosomal DNA is denatured but plasmid DNA is reversibly renatured. The method has been developed for the production of pharmaceutical grade DNA for use in in vivo and ex vivo gene therapy.

Abstract: The invention relates to a method for isolating anionic organic substances from aqueous systems using polymer nanoparticles with cationic pH-sensitive surface groups. Extraction can be carried out directly from diluted solutions, biological media (blood plasma, serum, urine, etc.) and complex buffer systems (e.g. PCR preparations contain detergents) without prior derivatization of the samples or addition of binding buffers. After separation from the surrounding medium the conjugates of the corresponding substances and polymer nanoparticles obtained in this manner can be purified through additional washing steps and effectively desalinated. Owing to the pH-sensitivity of the basic surface groups, the bound substances can be released in a targeted manner after separation by modification of the pH of the medium. By using volatile bases contamination of the released samples with ionic residues can be avoided.

Abstract: New compositions and methods for treating patients suffering from hepatitis-C, AIDS, aberrant apoptosis which include N-acetyl-D-glucosaminyl(&bgr;-1-4)-N-Acetyl-muramyl-L-ananyl-D-isoglutamine (GMDP) of at least 98% purity and provided either alone, as an active ingredient of blastolysine, or in combination with an aminosugar such as N-acetyl-glucosamine(NAG). The high purity GMDP has a decreased amount immunogenic impurities and demonstrates cell protection as opposed to solely immunostimulatory effects, while a synergistic cell protective effect is exhibited when GMDP in combined with NAG. The new compositions modulate FasL mediated apoptosis while simultaneously stimulating TNF-&agr; production and further selectively inhibiting TNF-&agr; receptor p55 (TNFR1), providing a treatment for patients suffering from hepatitis-C, AIDS or aberrant apoptosis.

Abstract: An apparatus for predicting a residual hormone concentration in a patient after a removal of a portion of the patient's glandular tissue which secretes the hormone, includes an input device constructed to receive a plurality of measured hormone concentrations corresponding to a plurality of human fluid samples taken from a patient at a plurality of sample times, respectively; and further includes a computer processor configured to iteratively calculate a residual hormone concentration. In accordance with one feature of the present invention, the computer processor is configured to generate data denoting a residual amount of glandular tissue that will remain in the patient after the removal of the portion of the patient's glandular tissue; and the apparatus further comprises an output device constructed to output the generated data denoting the residual amount of glandular tissue.

Abstract: A scalable method for the production of highly purified plasmid DNA in Escherichia coli is described, which method includes growing plasmid-containing cells to a high biomass in exponential growth and lysing the cells by raising the pH of the culture to a carefully controlled pH value in which chromosomal DNA is denatured but plasmid DNA is reversibly renatured. The method has been developed for the production of pharmaceutical grade DNA for use in in vivo and ex vivo gene therapy.

Abstract: The present invention discloses a new method for the purification of vancomycin hydrochloride by preparative HPLC (method of displacement chromatography), whereby the chromatographic purity of the product is essentialy improved.The chromatography is performed on a reverse stationary phase with a mobile phase consisting of an organic or inorganic acid or of a buffer with possible additives, with different displacing agents, at a defined pH and temperature as well as the amount and concentration of vancomycin hydrochloride.The process is distinguished by the excellent yield and exceptional chromatographic purity 95.5% area of the obtained product and, besides, it represents an ecologically irreproachable process.The vancomycin hydrochloride purified according to the present invention is useful for all types of application since the portion of impurities it contains is for one third lower than in hitherto known commercially available products.

Abstract: The present invention discloses a new process for the purification of vancomycin hydrochloride by combining preparative chromatography on a silica gel column and the precipitation with ethanol from a salt-water-ethanolic solution without intermediary filtering, whereby the chromatographic purity of the product is improved.The chromatography is carried out on a column containing a silica gel stationary phase and an alkaline water-methanolic mobile phase at defined pH, mobile phase flow and temperature as well as the amount and concentration of vancomycin hydrochloride. The process is distinguished by the yield and chromatographic purity of the obtained product of about 93% area.Vancomycin hydrochloride purified according to the present invention is useful for peroral as well as parenteral administration since the portion of impurities it contains is for one third smaller than in hitherto available product.

Abstract: The disclosure describes highly specific tryptase polyclonal antibodies, and a method to purify the antibodies. Specifically, the invention relates to polyclonal antibodies which have the capacity to capture tryptase out of solution, a process to generate the antibodies, and an enzyme-linked immunosorbent assay (ELISA) for human tryptase which utilizes the antibodies.

Abstract: The present invention provides an affinity separation method involving dynamic filtration.

Abstract: The present invention is directed to new antibiotic substances denominated antibiotic GE 2270 factors A.sub.1, A.sub.2, A.sub.3 and H, the addition salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them.

Abstract: The present invention is directed to new antibiotic substances denominated antibiotic GE 2270 factors A.sub.1, A.sub.2, A.sub.3 and H, the additional salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them.

Abstract: An antimycotic agent having a high degree of antimicrobial activity towards Eumycetes and with a level of toxicity lower than that of heptaene antibiotic V-28-3 is disclosed. This compound is a methyl ester derivative of heptaene antibiotic V-28-3.

Abstract: A method for producing a novel antifungal product from a Pediococcus species is described. The preferred product (AFP) comprises a compound which contains valine and lactic acid and has a molecular weight of less than about 500 daltons. The product (AFP) is particularly useful in retarding fungal growth in foods and other materials in need thereof.

Abstract: Imidazole/vancomycin complexes are prepared by containing an imidazole, preferably imidazole or N-methylimidazole, with a member of the vancomycin family, preferably Vancomycin itself.The complexes are useful in the purification of vancomycin.

Abstract: A novel antibiotic, A 42867, is prepared by cultivating the strain Nocardia sp. ATCC 53492, or an antibiotic A 42867-producing mutant or variant thereof, under submerged aerobic conditions in the presence of assimilable sources of carbon, nitrogen and inorganic salts. The antibiotic and its addition salts are useful in the treatment of infectious diseases and as growth promotant agents.

Abstract: A novel complex designated herein as rigolettone complex is produced by fermentation of Streptomyces aburaviensis strain C-38,242 (ATCC 39290). The complex and its purified bioactive components, jildamycin and mantuamycin, exhibit antitumor activity in mouse tumor systems.

Abstract: Antibiotic A26201-1 and antibiotic A26201-2 are produced by the novel microorganism, Actinoplanes species A26201 (ATCC 39573), under aqueous aerobic fermentation conditions. The antibiotics are useful for inhibiting bacteria, particularly gram positive bacteria, and are also useful for promoting the growth of monogastric and ruminant animals.

Abstract: The invention refers to an individual antibiotic substance selected from the group consisting of Teichomycin A.sub.2 factor 1, Teichomycin A.sub.2 factor 2, Teichomycin A.sub.2 factor 3, Teichomycin A.sub.2 factor 4 and Teichomycin A.sub.2 factor 5 in substantially pure form, and to the method of producing them by recovery from Teichomycin A.sub.2, a known antibiotic substance, by means of high-efficiency chromatographic methods. The single pure Teichomycin A.sub.2 factor 1, Teichomycin A.sub.2 factor 2, Teichomycin A.sub.2 factor 3, Teichomycin A.sub.2 factor 4 and Teichomycin A.sub.2 factor 5 are biologically distinguishable from Teichomycin A.sub.2 in that they have a higher degree of antibiotic activity against susceptible microorganisms.

Abstract: A method for extracting large quantities of an active biological factor that restores contact inhibition of growth to malignant cell types of different mammalian species.

Abstract: A dry preparation having a foam-like and, respectively, fleece-like structure obtained by freeze-drying consists, apart from thrombin in at least catalytically active amounts, substantially of approx. 10 to 95% by weight of fibrin and approx. 5 to 90% by weight of fibrinogen. For the preparation thereof, fibrin is produced in situ in an aqueous solution containing fibrinogen and thrombin and the resultant reaction mixture is deep-frozen and lyophilized. As further constituents of the dry preparation active substances such as e.g. antibiotics, natural bone material and/or a synthetic, bone-forming substitute, glycoproteins, coagulation-conducive substances and the like and/or fibrinolysis inhibitors come into consideration. The dry preparation is provided mainly for use as a wound toilet material, as a filling material for bone cavities and/or as a supporting material for further active substances.

Abstract: Purification of glycopeptide antibiotics actaplanin and vancomycin by adsorption on non-functional resins followed by elution of the antibiotic from the resin with aqueous solvents.

Abstract: Disclosed and claimed is an improved fermentation process for preparing the known antibiotic U-43,120, herein referred to as paulomycin. Also disclosed and claimed are the novel and useful antibiotics paulomycin A and paulomycin B.

Abstract: A process for preparing a porous solid material for use in a chromatography column and which is capable of fixing reversibly biological macromolecules comprises coating a porous inorganic support with a polysaccharide polymer having .alpha.-glycol groups which undergo oxidative scission, subjecting the polysaccharide polymer to an oxidative scission reaction, reacting the resulting oxidized polysaccharide polymer with an amino molecule or macromolecule having the formula R'--NH.sub.2 to produce a polysacchride polymer having the formula R.sub.4 --CH.dbd.N--R' and reducing the imine bond in said immediately above defined polysaccharide polymer to a stable amine bond.

Abstract: Antibiotic acanthomycin (U-53,827) produced by the controlled fermentation of the microorganism Streptomyces espinosus subsp. acanthus, NRRL 11081. This antibiotic and its base addition salts are active against Gram-positive bacteria. Accordingly, they can be used in various environments to eradicate or control such bacteria.

Abstract: Novel antibiotic U-59,761 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Saccharopolyspora hirsuta strain 367, NRRL 12045. This antibiotic is active against various microorganisms, for example, Staphylococcus aureus, Streptococcus pyogenes, Sarcina lutea, Klebsiella pneumoniae, Mycobacterium avium, and Bacteroides fragilis. Thus, antibiotic U-59,761 can be used in various environments to eradicate or control such bacteria.

Abstract: Fermentation broths or impure solutions containing thienamycin, a substance having antibiotic activity against gram-negative and gram-positive microorganisms, are purified using a sequence of ion exchange resins, starting with an anion exchange resin of the polystyrene-trimethylammonium type in the HCO.sub.3 -cycle, and ending with absorption on and elution from a polymeric cross-linked polystyrene-type resin adsorbent. Variations in the intermediate steps, e.g. different resins and eluates are possible and are illustrated within.

Abstract: It has been found that a novel antibiotic can be obtained by the fermentation of certain strains of Streptomyces olivaceus and related organisms. In addition to being a potent antibiotic this new material which we have designated MM 13902 acts synergistically with penicillins and cephalosporins.

Abstract: It has been found that an antibiotic can be obtained by the fermentation of certain strains of Streptomyces olivaceus and related organisms and when pure this antibiotic is an extremely potent inhibitor of many .beta.-lactamases. This antibiotic which we designate MM 4550A may be obtained in substantially pure form by the chromatographic purification of the crude antibacterial complex obtained from the culture medium.

Abstract: Fermentation broths or impure solutions containing thienamycin, a substance having antibiotic activity against gram-negative and gram-positive microorganisms, are isolated using liquid ion exchange systems.

Abstract: A novel antibiotic designated herein MM 17880 may be obtained from the cultivation of strains of Streptomyces olivaceus and related organisms. In addition to being potent antibacterial agents, MM 17880 and its salts inhibit .beta.-lactamase obtained from may organisms so that it shows a synergistic antibacterial effect when combined with .beta.-lactam antibiotics.